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2 
Abstract  22 
Perfluorooctanoic acid (PFOA) has recently attracted attention as a potential health risk 23 
following environmental contamination. However, information detailing exposure to 24 
perfluorinated carboxylic acids (PFCAs) other than PFOA is limited. We measured the 25 
concentrations of PFCAs (from perfluorohexanoic acid to perfluorotetradecanoic acid) 26 
in serum samples obtained from patients in Japan (Sendai, Takayama, Kyoto and Osaka) 27 
between 2002 and 2009, Korea (Busan and Seoul) between 1994 and 2008 and Vietnam 28 
(Hanoi) in 2007/2008. Total PFCAs levels (geometric mean) were increased from 8.9 ng 29 
mL
-1
 to 10.3 ng mL
-1
 in Japan; from 7.0 ng mL
-1
 to 9.2 ng mL
-1
 in Korea; and were 30 
estimated at 4.7 ng mL
-1
 in Vietnam. PFCAs of greater length than PFOA were 31 
significantly increased in Sendai, Takayama and Kyoto, Japan, and levels of long-chain 32 
PFCAs exceeded PFOA levels in serum. Among these PFCAs, perfluoroundecanoic 33 
acid (PFUnDA) was the predominant component (28.5%), followed by 34 
perfluorononanoic acid (PFNA 17.5%), perfluorodecanoic acid (PFDA 7.9%), 35 
perfluorotridecanoic acid (PFTrDA 6.1%) and perfluorododecanoic acid (PFDoDA 36 
1.8%). Odd-numbered PFCAs (PFNA, PFUnDA and PFTrDA) were also observed in 37 
Korea and Vietnam and their presence increased significantly in Korea between 1994 38 
and 2007/2008. The proportion of long-chain PFCAs in serum was relatively high 39 
compared to reports in Western countries. Further investigations into the sources and 40 
exposure routes are needed to predict the future trajectory of these serum PFCA levels. 41 
Key words: perfluorocarboxylate; perfluorooctanoic acid; serum; temporal trend; 42 
East Asia 43 
3 
Abbreviations 44 
PFCAs: perfluorinated carboxylic acids 45 
PFOS: perfluorooctane sulfonate 46 
PFOA: perfluorooctanoic acid 47 
PFHxA: perfluorohexanoic acid 48 
PFHpA: perfluoroheptanoic acid 49 
PFNA: perfluorononanoic acid 50 
PFDA: perfluorodecanoic acid 51 
PFUnDA: perfluoroundecanoic acid 52 
PFDoDA: perfluorododecanoic acid 53 
PFTrDA: perfluorotridecanoic acid 54 
PFTeDA: perfluorotetradecanoic acid 55 
IDLs: instrumental detection limits 56 
MDLs: method detection limits 57 
RSD: relative standard deviation 58 
SD: standard deviation 59 
GM: geometric mean 60 
GSD: geometric standard deviation 61 
62 
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1. Introduction 63 
Perfluorinated compounds such as perfluorooctane sulfonate (PFOS) and 64 
perfluorooctanoic acid (PFOA) have recently attracted attention owing to widespread 65 
contamination of the environment, wildlife and humans by these chemicals (Houde et 66 
al., 2006). In 2002, after 50 years of production, 3M Company phased out their 67 
manufacture of PFOS (Renner, 2001). PFOA is considered to be a major component of 68 
perfluorocarboxylates (PFCAs) emission. However, in Japan, PFCA emissions consisted 69 
of not only PFOA but also perfluorononanoic acid (PFNA) and perfluoroundecanoic 70 
acid (PFUnDA) (of which 25 and 7 metric tons, respectively, were emitted in 2000) 71 
(Prevedouros et al., 2006). These odd-numbered PFCAs (PFNA, PFUnDA and 72 
perfluorotridecanoic acid (PFTrDA)) were detected at higher concentrations in samples 73 
from local wildlife than similar even-numbered PFCAs (PFOA, perfluorodecanoic acid 74 
(PFDA) and perfluorododecanoic acid (PFDoDA), respectively) (Furdui et al., 2008). 75 
Although studies using human samples from Western countries showed that PFOA was 76 
the most prevalent (followed by PFNA, PFDA and PFUnDA) (Haug et al., 2009; 77 
Joensen et al., 2009; Kato et al., 2009), our previous study of Japanese women in the 78 
Miyagi prefecture showed that PFNA and PFUnDA (average: 2.8 and 5.4 ng mL
-1
, 79 
respectively) were found at broadly similar serum concentrations to PFOA (average: 4.9 80 
ng mL
-1
) (Kärrman et al., 2009). 81 
PFCAs with longer chains than PFOA have higher bio-concentration factors 82 
suggesting persistency in the environment (Martin et al., 2003). Temporal trends in 83 
serum levels after 2002 showed no apparent decline of PFNA, PFDA or PFUnDA in 84 
Norway (Haug et al., 2009), although serum levels of PFOA and PFOS both decreased 85 
in the United States, Norway and Japan (Harada and Koizumi, 2009; Harada et al., 86 
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2010; Haug et al., 2009; Olsen et al., 2008). These findings suggest a possibility that the 87 
origin and source of exposure to long-chain PFCAs could differ from those of PFOA 88 
and PFOS. 89 
In the present study, we investigated current serum concentrations of PFCAs in three 90 
Asian countries (Japan, Korea and Vietnam). We selected the cities of Busan and Seoul 91 
in Korea because they are comparably urban and industrialized to Osaka, Japan. To 92 
confirm the temporal trends in Japan and Korea, we used archived historical serum 93 
samples stored in the human specimen bank (Koizumi et al., 2009; Koizumi et al., 94 
2005). Hanoi in Vietnam was selected to evaluate the development of PFCA 95 
contamination following recent industrialization. 96 
 97 
2. Material and methods   98 
2.1. Experimental design and study population  99 
To evaluate geographical differences and temporal trends in Asian countries, we 100 
compared 521 samples collected from Japan (Sendai, Takayama, Kyoto and Osaka) 101 
between 2002 and 2009; Korea (Busan and Seoul) between 1994 and 2008; and in 102 
Hanoi, Vietnam between 2007 and 2008. Samples from Sendai and Takayama in 2008, 103 
Osaka, Busan, Seoul and Hanoi are identical to a previous analysis of PFOS and PFOA 104 
(Harada et al., 2010; Kärrman et al., 2009). A total of 521 serum samples with 105 
information on donor age, sex and residential history (>5 yr in each area) were selected 106 
from the archived samples in Kyoto Human Specimen Bank (Koizumi et al., 2009; 107 
Koizumi et al., 2005) (Table 1). Serum was separated from cellular components and 108 
stored at -30 °C until analysis. 109 
The study population in Osaka and Kyoto consisted of residents that had been 110 
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intensely exposed to PFOA from a local industrial source (the fluoropolymer 111 
manufacturer, Daikin Company) (Harada et al., 2004, 2007, 2010; Kärrman et al., 2009; 112 
Niisoe et al., 2010). In contrast, there is no known potential industrial source of PFCAs 113 
that would affect sample populations in the other cities studied. 114 
For historical comparisons, samples were selected so that age and gender were 115 
matched among time points, except for Busan in 2000 and Osaka (Table 1). 116 
The research protocol for the present study was reviewed and approved by the 117 
Ethics Committee of the Kyoto University Graduate School of Medicine on 14 118 
November 2003 (E25). 119 
 120 
2.2. Reagents 121 
Ammonium acetate (purity: >99% by HPLC) was purchased from Aldrich 122 
(Steinheim, Germany). Acetonitrile (LC-MS grade) and water (distilled LC-MS grade) 123 
were obtained from Kanto Chemicals (Tokyo, Japan). Acetic acid and benzyl bromide 124 
were purchased from Wako pure chemicals (Osaka, Japan). Mixture of native PFCAs, 125 
13
C4-labeled PFOA and 
13
C5-labeled PFNA were obtained from Wellington Laboratories 126 
(Guelph, Ontario, Canada). 127 
 128 
2.3. Determination of PFCAs in serum 129 
Perfluorohexanoic acid (PFHxA), perfluoroheptanoic acid (PFHpA), PFOA, PFNA, 130 
PFDA, PFUnDA, PFDoDA, PFTrDA and perfluorotetradecanoic acid (PFTeDA) were 131 
analyzed. Serum samples were subjected to a clean-up procedure using a dispersive 132 
carbon method described by Powley et al. (2005). Briefly, the serum samples (0.5 mL, 133 
except for Korean samples between 1994 and 2000, which were 0.25 mL) together with 134 
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an internal standard (
13
C4-PFOA, 1 ng) were extracted with 5 mL of acetonitrile, 135 
followed by centrifugation at 1600 × g for 15 min. The supernatants were transferred 136 
into new tubes with 25 mg of ENVI-Carb and 50 µL of acetic acid, and the solutions 137 
were mixed by vortexing for 30 s. After centrifugation at 1600 × g for 15 min, the 138 
extracts were dried under a nitrogen stream. The residue was then re-dissolved in 100 µl 139 
of 100 mM benzyl bromide acetone containing the recovery performance standard 140 
13
C5-PFNA (1 ng) for 1 hour at 80 °C and transferred to an autosampler vial. Extracts 141 
were analyzed using gas chromatography-mass spectrometry (Agilent 142 
6890GC/5973MSD, Agilent Technologies Japan, Ltd., Tokyo, Japan) in electron impact 143 
ionization mode using single ion monitoring. PFCA benzyl esters were separated on a 144 
DB-5MS column (30 m length, 0.25 mm i.d., 1 m film thickness) with a helium carrier 145 
gas. Split-less injections (1 l) were performed with the injector set at 220 °C, and the 146 
split was opened after 1.5 min. The initial oven temperature was 70 °C for 2 min, 147 
ramped at 20 °C min
-1
 to 100 C°, and then at 30 °C min
-1
 to 280 °C. Ion fragments 148 
([M]
+
) were monitored and used as quantification ions (Table 2). 149 
Instrumental detection limits (IDL) were defined as the mass of analyte producing a 150 
peak with a signal-to-noise ratio of 3, and ranged from 1 pg (PFTeDA) to 0.25 pg (other 151 
PFCAs) (Table 2). Since blank samples (0.5 mL distilled water) contain no detectable 152 
concentrations, the method detection limits (MDL) value was considered to be equal to 153 
the IDL corresponding to 0.2 ng mL
-1
 for PFTeDA and 0.025 ng mL
-1
 for other PFCAs 154 
(Table 2). 155 
 156 
2.4. Quality assurance 157 
Quantification was performed using an internal standard method with the external 158 
8 
standards dissolved in 10% methanol in water. 
13
C4-PFOA was used as the internal 159 
standard for PFCAs. 
13
C5-PFNA was used to calculate a recovery rate of 
13
C4-PFOA. 160 
All samples were quantified using a seven-point calibration curve with a relative 161 
standard deviation (RSD) of the relative response factors <15% for all compounds. The 162 
recoveries were evaluated by five replicate fortifications (fortified by 10 times the 163 
original concentration of serum) of a human serum sample with low contamination 164 
(Table 2). The procedural blank levels were evaluated in duplicate for 11 samples each 165 
using 0.5 mL distilled water. 166 
Using the above method, we reanalyzed 361 samples originally tested in a previous 167 
study by HPLC-MS/MS (Harada et al., 2010; Kärrman et al., 2009). The reanalyzed 168 
samples showed 5.14±11.60 ng mL
-1
 for PFOA, which equates to 101.7% of the levels 169 
obtained in the previous study (5.05±11.16 ng mL
-1
, p=0.478 by paired t-test). Pearson’s 170 
correlation coefficient, r and slope were 0.9882 and 1.128, respectively (p<0.0001). 171 
Levels (mean±SD) of PFHpA, PFNA, PFDA and PFUnDA in Osaka in 2004 were also 172 
confirmed in this study (HPLC-MS/MS vs GC-MS: 0.26±0.14 ng mL
-1
 vs 0.24±0.09 ng 173 
mL
-1
, 6.68±1.78 ng mL
-1
 vs 6.16±1.91 ng mL
-1
, 2.55±0.99 ng mL
-1
 vs 2.74±1.32 ng 174 
mL
-1
, 5.80±2.13 ng mL
-1
 vs 5.12±2.69 ng mL
-1
, respectively; p>0.05 by paired t-test). 175 
RSDs of difference between methods were 33.1%, 9.8%, 13.6% and 11.5% for PFHpA, 176 
PFNA, PFDA and PFUnDA, respectively and average RSD was 17.0%. 177 
To assess potential interlaboratory difference in analysis, NIST standard reference 178 
material (SRM) 1957 was analyzed (Table 2). The values from PFHpA to PFUnDA 179 
were comparable to those from interlaboratory comparison exercises (Lindstrom et al., 180 
2009; Keller et al., 2010). 181 
Mean recovery rate (RSD) of 
13
C4-PFOA in 521 samples was 96.5% (8.8%). To 182 
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evaluate possible matrix effect in serum sample, we further analyzed 100 samples 183 
extracts fortified with 1 ng of PFHpA, PFNA, PFDA, PFUnDA, PFDoDA and PFTrDA 184 
standards. Recoveries of fortified standards were 98.7%, 104.6%, 102.0%, 97.2%, 185 
102.2% and 96.3% for PFHpA, PFNA, PFDA, PFUnDA, PFDoDA and PFTrDA, 186 
respectively. It is therefore considered that there was no substantial suppression or 187 
enhancement of target ions, if any.  188 
 189 
 190 
2.5. Statistical analysis 191 
All statistical analyses were carried out using the JMP software (Version 4; SAS 192 
Institute Inc., Cary, NC). Values of p<0.05 were considered to indicate statistical 193 
significance. Concentrations of less than the detection limit were all approximated to 194 
‘half of detection limit’ for statistical analyses. Serum levels of PFCAs were assumed to 195 
distribute lognormally because the serum levels of PFCAs in the samples displayed 196 
right-skewed patterns and geometric means were comparable to medians. Statistical 197 
analyses were conducted after logarithmic transformation of the serum concentrations. 198 
Differences between mean values were tested by Tukey-Kramer’s honestly significant 199 
difference (HSD) test after ANOVA. Correlation was tested by Spearman's rank 200 
correlation coefficient (ρ). Factor analysis was used to transform a number of 201 
contaminants into a smaller number of potential factors of sources. Factor analysis was 202 
conducted via correlation matrix. In essence, the factor analysis is a model which 203 
presumes the existence of a smaller set of factors that can reproduce exactly the 204 
correlation in the larger set of variable. To achieve this goal, the linier combinations of 205 
factors (i.e., principal component) will be generated in such a manner that each 206 
10 
composite variate will account a smaller portion of the total variation i.e., variance. 207 
Eigenvalues of a principal component is a measure how much this principal component 208 
can account for the variation and eigenvector indicates an associated set of coefficients 209 
with a principal component for each factor. Eigenvectors were employed through the 210 
analysis when eigenvalues were close to or greater than 1 which means its eigenvector 211 
can account the equivalent of one or more original variables. Normalized varimax 212 
rotation (an orthogonal rotation of the factor axes) was applied to these eigenvectors to 213 
simplify them into a few variables with high correlations. 214 
 215 
3. Results 216 
3.1. Temporal changes in PFCA concentrations in Japan 217 
The descriptive statistics for PFCAs are presented in Table 3. Most samples 218 
contained PFOA, PFNA, PFDA, PFUnDA and PFTrDA at both time points. No samples 219 
contained PFHxA and PFTeDA at concentrations above MDL. PFHpA levels were 220 
significantly decreased in all sampling sites in Japan between 2002/2004 and 2008/2009 221 
(p<0.05 by Student’s t-test). PFOA was relatively high in Osaka and Kyoto although 222 
levels of this compound nevertheless significantly decreased in this period (p<0.05 by 223 
Student’s t-test). In Sendai and Takayama, PFOA levels also decreased but this 224 
difference was not statistically significant. In contrast, PFCAs longer than PFOA 225 
showed significant increases in Sendai, Takayama and Kyoto with few exceptions. 226 
Among these PFCAs, PFUnDA was the predominant component, followed by PFNA, 227 
PFDA, PFTrDA and PFDoDA. These odd-numbered PFCAs (i.e. PFUnDA, PFNA and 228 
PFTrDA) were detected at higher concentrations than neighboring, even-numbered 229 
PFCAs (PFDA and PFDoDA). 230 
11 
In Osaka, levels of PFNA, PFDA and PFUnDA, as with PFOA, significantly 231 
decreased from 2004 to 2008. PFDoDA and PFTrDA levels did not change. Among four 232 
sampling sites in 2008/2009, Osaka and Kyoto had higher PFOA, PFNA and PFDA 233 
levels than Sendai and Takayama (p<0.05 by Tukey’s HSD test) but PFUnDA, PFDoDA 234 
and PFTrDA showed no regional differences (p>0.05 by ANOVA). 235 
As a consequence of the increase in long-chain PFCAs, the proportion of PFOA in the 236 
total PFCA content became less than 50% in all locations except Osaka. 237 
 238 
3.2. Temporal trends in the serum concentrations of PFCAs in Korea 239 
The PFCA concentrations in the serum samples collected in Busan and Seoul 240 
between 1994 and 2008 are shown in Table 4. As is the case with Japan, PFOA, PFNA, 241 
PFDA, PFUnDA and PFTrDA were frequently detected in 2007/2008. PFHxA and 242 
PFTeDA were not detected in any samples at concentrations above MDL. In agreement 243 
with the previous report by Harada et al. (2010), PFOA levels were stable from 1994 to 244 
2008 in Busan and Seoul (p>0.05 by ANOVA). In contrast, odd-numbered PFCAs 245 
(PFNA, PFUnDA and PFTrDA) were significantly increased during this period (p<0.05 246 
by Tukey’s HSD test or Student’s t-test). The PFCA levels had the following order of 247 
prevalence in 1994: PFOA>PFNA~PFUnDA>PFDA>PFTrDA>PFHpA~PFDoDA. 248 
However, by 2007/2008 the order had changed to: 249 
PFOA>PFUnDA>PFNA>PFDA~PFTrDA>PFDoDA>PFHpA. Between 1994 and 250 
2007/2008, total PFCA levels were significantly increased by 1.31- and 1.53-fold in 251 
Busan and Seoul, respectively (p<0.05 by Tukey’s HSD test or Student’s t-test). 252 
Samples from Busan contained higher concentrations of PFHpA, PFOA, PFNA, PFDA, 253 
PFUnDA and PFTrDA than did those from Seoul in both 1994 and 2007/2008 (p<0.05 254 
12 
by Student’s t-test). 255 
 256 
3.3. PFCAs concentrations in Hanoi, Vietnam in 2008-2009 257 
PFOA, PFNA, PFDA and PFUnDA were detected in all samples, and PFDoDA and 258 
PFTrDA were also detected, albeit less frequently (Table 5). PFHxA, PFHpA and 259 
PFTeDA were not detected in any samples from Hanoi. The concentration of PFUnDA 260 
was highest among the PFCAs studied, followed by PFNA, PFDA, PFOA, PFTrDA and 261 
PFDoDA. The proportion of PFOA relative to total PFCAs was only 12.9%. 262 
 263 
3.4. Correlations among PFCA levels and factor analysis 264 
Correlation coefficients among PFCAs in 521 samples are listed in Table 6. PFHpA 265 
was relatively less correlated with other PFCAs, except for PFOA (ρ=0.398). PFOA also 266 
significantly correlated with PFNA and PFDA (ρ coefficient >0.5) but was less well 267 
correlated with PFUnDA, PFDoDA and PFTrDA. In general, PFCA concentrations 268 
indicated a strong correlation between PFCAs of similar (i.e. adjacent) chain length. 269 
To delineate potential patterns in the data, PFCA concentrations were examined 270 
using factor analysis. The contributions of factors 1 and 2 to the total variance were 271 
49.72% and 19.40% (with an eigenvalue >1), respectively (Table 7). After varimax 272 
rotation, the first factor indicated a higher eigenvector for longer-chain PFCAs than 273 
PFNA. The second factor had a more positive eigenvector for shorter-chain PFCAs than 274 
PFDA. Since there is a point source of PFCAs in both Osaka and Kyoto, we evaluated 275 
whether this predominant source may perturb the results of the factor analysis. 276 
Eliminating Osaka and Kyoto samples, however, did not alter a correlation matrix 277 
among PFCAs with changes in eigenvalues being less than 5% (data not shown), 278 
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indicating that the dominant point source had no substantial influence on the 279 
interpretation of factor 1 and factor 2. 280 
Factor 1 is characterized by PFUnDA dominance (factor loading: 0.858) and another 281 
by PFOA dominance (0.819), respectively. This characteristic pattern indicates 282 
fingerprints of PFCAs sources in Asia. Temporal transition of factor scores is 283 
demonstrated by score plots shown in Supplemental Fig. 1. In sampling sites in Japan 284 
and Korea (except for Osaka), centers of score plot moved rightwards and downwards, 285 
indicating that the factor 1 score increased and factor 2 score decreased during these 286 
periods. Mean factor scores of each sampling site are also shown in Table 7. In Japan, 287 
factor 1 scores significantly increased from 2002/2003 to 2008/2009 (p<0.05 by 288 
Student’s t-test), except for Osaka which already had a high factor 1 score (0.92) in 289 
2004. This increase in factor 1 scores was also observed in Busan and Seoul from 1994 290 
to 2007/2008 (p<0.05 by Tukey’s HSD test or Student’s t-test). Although the factor 1 291 
score in Hanoi was lower than those in other sites in 2007–2009, it surpassed scores in 292 
Sendai and Kyoto in 2002/2003 and in Busan and Seoul in 1994. Contrary to factor 1, 293 
factor 2 scores in all sampling sites in Japan significantly declined between 2002/2004 294 
and 2008/2009 (p<0.05 by Student’s t-test) and also in Busan and Seoul from 1994 to 295 
2007/2008 (p<0.05 by Tukey’s HSD test or Student’s t-test). Factor 2 in Hanoi was the 296 
lowest among all sampling sites. 297 
 298 
4. Discussion 299 
In the present study, we uncovered two major fingerprints (factor 1 and factor 2) by 300 
analyzing serum samples from three countries in East Asia. Characteristic PFCA 301 
composition was observed for odd-numbered PFCAs such as PFUnDA and PFTrDA 302 
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with residual PFDoDA and PFDA, which can correspond to factor 1. Even in 303 
populations exposed to low levels of PFOA, notably Hanoi, PFUnDA showed 304 
substantial serum levels. Moreover, levels of those PFCAs with longer chain lengths 305 
than PFOA were significantly elevated in Japan and Korea in recent years. In the 306 
late-2000s, consequently, long-chain PFCA levels exceeded PFOA levels in most 307 
sampling sites. This finding suggests an emergence of specific sources of exposure in 308 
East Asia. 309 
In several countries, serum PFOA has reportedly decreased (Harada et al., 2010; 310 
Olsen et al., 2008). In contrast, PFCAs of longer chain lengths than PFOA were 311 
frequently detected in serum samples in this study. Total levels of long-chain PFCAs 312 
were comparable to or greater than PFOA levels (except in Osaka) and showed trends 313 
towards increases in Japan and Korea. Correlation between PFOA and long-chain 314 
PFCAs was not strong which suggests that the sources of long-chain PFCA 315 
contamination have different exposure route than PFOA. Indeed, factor analysis 316 
demonstrated two major factors as sources of PFCAs. The first factor had loading on 317 
longer-chain PFCAs than PFOA and the second factor on PFHpA, PFOA and PFNA. 318 
Temporal trends of these factors were opposite and contamination derived from factor 1 319 
might be expected to emerge in around a decade. This transition of factor scores was 320 
similar in Japan, Korea and Hanoi. Contamination derived from factor 1 may have been 321 
prevailing in East Asian countries. 322 
Among long-chain PFCAs, odd-numbered PFCAs accounted for the major 323 
proportion. Serum or blood levels of PFCAs reported from populations in China, Sri 324 
Lanka, Australia, Norway, Sweden, Denmark, Poland, Belgium, Spain and USA are 325 
summarized in Table 8 (Ericson et al., 2007; Falandysz et al., 2006; Guruge et al., 2005; 326 
15 
Haug et al., 2009; Joensen et al., 2009; Kärrman et al., 2006; Kuklenyik et al., 2004; 327 
Pan et al., 2010; Roosens et al., 2010; Toms et al., 2009). The PFCA composition in our 328 
current study, which was characterized by a large proportion of PFUnA, was apparently 329 
different from Western countries (Table 8). Although PFOA levels in these countries 330 
were comparable, long-chain PFCAs were not major components in Western countries, 331 
except for Antwerp, Belgium and Atlanta, USA. Therefore, this composition can be 332 
considered as a clear fingerprint for East Asian countries and is implicated in the 333 
origination of factor 1. 334 
However, their source remains unclear due to insufficient monitoring data of PFCAs. 335 
Interestingly, a review by Prevedouros et al. (2006) indicated that PFNA has been 336 
manufactured in Japan via oxidation of fluorotelomer olefins together with PFUnDA 337 
and PFTrDA. Industrial application of these odd-numbered PFCAs, namely Surflon 338 
S-111, might contribute to the East Asian-specific pattern of serum body burdens. The 339 
temporal increase in long-chain PFCAs warrants further investigations of the sources 340 
and exposure routes to assist in predicting future changes in the serum levels of these 341 
contaminants. 342 
In this study, there was a limitation in chemical analysis. 
13
C4-PFOA was used for 343 
internal standard for PFCAs (C7-C14). Chemical properties of PFCAs may, however, be 344 
different even though they have similar structures. Matrix effects also might affect 345 
quantification of PFCAs other than PFOA. Thus it is logically possible that recovery 346 
rates of 
13
C4-PFOA might be extensively deviated from those of other PFCAs. 347 
Neverthelss, such a possibility is unlikely because recovery rates of PFCAs were higher 348 
than 90% and RSD were within 10%, indicating that there was no substantial difference 349 
in recoveries among PFCAs in this method. Furthermore, a good agreement of results  350 
16 
in SRM analysis by interlaboratory comparisons assured that our analytical method in 351 
this study is sound. Collectively,  these findings consistently support that analytical 352 
method in this study was sufficiently qualified. 353 
Recent epidemiological investigations have raised concern regarding developmental 354 
effects of PFOA on children (Steenland et al., 2010). In contrast, few studies have been 355 
conducted on the effects of PFCAs of different chain length. Even though PFCAs have 356 
similar structure, their chemical properties and biological activity are likely different. In 357 
several in vitro studies, long-chain PFCAs caused biological responses at lower doses 358 
than PFOA (Liao et al., 2009; Matsubara et al., 2006; Upham et al., 1998). The 359 
toxicokinetics of long-chain PFCAs are also unclear, especially in humans. These 360 
uncertainties necessitate more comprehensive toxicological studies on PFCAs. 361 
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Figure captions 482 
Supplemental Fig. 1. 483 
Plot of first- and second factor scores of 521 samples in Osaka (A), Kyoto (B), 484 
Takayama (C), Sendai (D), Busan (E) and Seoul and Hanoi (F). Overall, 50% of the 485 





Study area and study population
Sampling site Population (x10
3




Sendai 1,031 38°17'04" N 140°55'46" E 2008 50 (100) 37.5±9.44 (21-53)
1,023 - 2003 50 (100) 36.6±10.1 (20-59)
Takayama 94 (65)
b
36°08'13" N 137°15'16" E 2008 50 (100) 40.5±4.78 (29-49)
67 - 2003 50 (100) 39.9±4.5 (31-45)
Kyoto 1,466 35°01'18" N 135°46'38" E 2009 30 (50) 33.2±14.7 (21-68)
1,469 - 2002 30 (50) 35.4±11.3 (21-58)
Osaka 2,652 34°45'31" N 135°31'52" E 2008 50 (100) 45.9±8.92
A*
(30-63)




Busan 3,711 35°14'39" N 129°05'54" E 2008 35 (100) 40.1±6.44
A*
(18-49)
3,732 - 2000 30 (100) 35.4±4.27
B
(28–45)
3,961 - 1994 39 (100) 42.3±4.65
A
(34-52)
Seoul 10,421 37°27'52" N 127°01'56" E 2007 36 (100) 34.5±8.24 (20-54)
10,798 - 1994 24 (100) 38.0±7.41 (24-51)
Vietnam
Hanoi 6,232 21°00'08" N 105°49'50" E 2007-2008 37 (100) 30.2±5.76 (20-40)
a Data are presented as mean ± standard deviation.
* Means of age with different letters differed significantly (p<0.05 by Tukey's HSD test). For example, the
letters A and B indicate that the corresponding values differ significantly at p<0.05.
b Takayama city merged with neighboring cities in 2005. Numbers in paretheses denote populations areas
corresponding to those used in 2003.
Table 2
Recovery, detection limits and QA for PFCA analysis in human serum samples






 (confirmation) %  (RSD%)
a 
(n=5)  limit 
b







PFHxA 404 (385) 92.2 (8.41) 0.25 0.05 <0.05
PFHpA 454 (435) 94.5 (4.12) 0.25 0.05 0.27
PFOA 504 (485) 101.7 (6.99) 0.25 0.05 4.77
13
C4 PFOA 508 (489) 102.8 (5.47) - - -
PFNA 554 (535) 97.4 (7.61) 0.25 0.05 0.96
13
C5 PFNA 559 (540) - - - -
PFDA 604 (585) 91.9 (8.63) 0.25 0.05 0.26
PFUnDA 654 (635) 94.1 (7.22) 0.25 0.05 0.16
PFDoDA 704 (685) 95.7 (4.87) 0.5 0.1 <0.1
PFTrDA 754 (735) 98.6 (9.41) 0.5 0.1 <0.1
PFTeDA 785 (786) 92.4 (8.18) 1 0.2 <0.2
a




0.5 mL serum sample
d 
0.5 mL serum sample of NIST SRM 1957 was analyzed.
Table 3
Serum concentrations of PFCAs in Japan
Sampling Concentration (ng mL
-1
)
site Year n PFHpA PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA ΣPFCAs
Sendai 2008 50 GM(GSD) 0.06(2.17)* 2.44(1.56) 1.80(1.40)*0.72(1.46)*3.00(1.59)*0.17(1.99)*0.60(2.00)* 9.13(1.41)*
range <0.05-0.37 0.85-6.05 0.90-3.58 0.31-1.58 1.15-8.08 <0.1-0.52 <0.1-1.43 3.81-17.52
detection% 58 100 100 100 100 82 96
2003 50 GM(GSD) 0.15(3.75) 2.65(1.61) 1.01(1.85) 0.52(1.71) 1.68(1.75) 0.10(1.85) 0.31(2.12) 6.92(1.51)
range <0.05-1.25 0.87-7.59 0.21-4.94 0.09-1.57 0.32-5.70 <0.1-0.37 <0.1-1.13 2.74-17.94
detection% 72 100 100 100 100 58 100
Takayama 2008 50 GM(GSD) 0.04(2.29)* 2.51(1.84) 1.78(1.42)*0.85(1.51)* 3.12(1.51) 0.20(2.15)* 0.60(2.66) 9.87(1.39)
range <0.05-0.49 0.82-11.25 1.01-4.50 0.26-2.68 1.28-7.13 <0.1-0.61 <0.1-2.46 5.44-22.09
detection% 38 100 100 100 100 82 94
2003 50 GM(GSD) 0.11(2.35) 3.19(1.62) 1.30(1.73) 0.65(1.63) 2.74(1.60) 0.14(1.88) 0.55(1.72) 9.18(1.49)
range <0.05-1.72 1.36-20.28 0.64-9.88 0.18-2.26 0.77-7.81 <0.1-0.51 0.16-1.98 4.49-37.04
detection% 88 100 100 100 100 80 100
Kyoto 2009 30 GM(GSD) 0.11(1.98)* 5.28(1.57)* 2.78(1.42)* 1.10(1.45) 3.20(1.64)*0.24(1.87)*0.45(1.57)* 13.67(1.42)
range <0.05-0.31 2.60-16.52 1.34-4.40 0.60-2.25 1.20-11.26 <0.1-0.99 0.22-1.15 6.60-26.81
detection% 96.7 100 100 100 100 93.3 100
2002 30 GM(GSD) 0.23(1.89) 7.12(1.54) 2.09(1.67) 0.91(1.66) 1.89(1.65) 0.12(2.04) 0.31(1.83) 12.98(1.52)
range 0.08-1.25 2.69-19.64 0.81-5.37 0.35-2.54 0.72-5.44 <0.1-0.37 <0.1-1.00 5.38-33.75
detection% 100 100 100 100 100 66.7 96.7
Osaka 2008 50 GM(GSD) 0.07(3.11)* 13.46(1.79)*3.54(1.62)*1.11(1.60)*3.05(1.73)* 0.16(2.55) 0.52(2.62) 23.08(1.64)*
range <0.05-1.11 5.59-201.68 0.85-14.57 0.36-2.80 1.01-8.79 <0.1-0.75 <0.1-1.95 10.77-220.07
detection% 48 100 100 100 100 68 94
2004 10 GM(GSD) 0.21(2.00) 29.54(1.29) 6.41(1.38) 2.38(1.48) 5.45(1.46) 0.25(2.28) 0.44(2.40) 45.42(1.27)
range 0.05-0.45 20.60-45.20 3.07-9.22 1.41-4.17 3.19-9.01 <0.1-0.51 <0.1-1.02 31.67-65.57
detection% 100 100 100 100 100 90 90
* GMs between time points are significantly different in each sampling site (p<0.05 by Student's t test after log transformation).
GM: Geometric mean; GSD: Geometric standard deviation
Table 4
Serum concentrations of PFCAs in Korea
Sampling Concentration (ng mL
-1
)
site Year n PFHpA PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA ΣPFCAs












range <0.05-0.16 2.77-9.80 1.02-3.89 0.44-1.76 1.03-7.62 <0.1-0.81 <0.1-2.74 6.70-24.13
detection% 40 100 100 100 100 85.7 97.1












range <0.1-0.28 1.19-7.33 0.89-3.61 0.32-1.47 0.58-3.95 <0.20-0.39 <0.20-1.73 4.31-16.00
detection% 30 100 100 100 100 33.3 100












range <0.1-0.32 1.72-9.63 <0.10-5.20 0.25-2.98 <0.20-13.16 <0.20-1.03 0.10-2.89 4.08-32.50
detection% 35.9 100 97.4 100 92.3 7.7 69.2
Seoul 2007 36 GM(GSD) 0.03(1.48) 2.29(1.34) 1.13(1.32)* 0.58(1.38) 2.18(1.48)* 0.12(2.03) 0.59(2.10)* 7.10(1.35)*
range <0.05-0.12 1.22-4.64 0.74-2.01 0.32-1.00 1.10-5.62 <0.10-0.38 <0.10-1.54 3.94-12.55
detection% 13.9 100 100 100 100 66.7 97.2
1994 24 GM(GSD) 0.08(1.00) 2.09(1.54) 0.65(2.01) 0.45(2.06) 0.54(3.89) 0.10(1.26) 0.16(2.40) 4.63(1.49)
range <0.1 0.89-4.09 <0.1-1.73 <0.1-1.18 <0.20-3.59 <0.20-0.31 <0.20-1.08 2.56-10.69
detection% 0 100 95.8 95.8 70.8 4.2 25
GM: Geometric mean; GSD: Geometric standard deviation
* GMs among different time points are significantly different  in each sampling sites (p<0.05 by Student's t test or Tukey's HSD test
after log transformation). Alphabetic suffix was used for comparisons among three groups. For example, the letters A and B indicate
that the corresponding values differ significantly at p<0.05., while A and AB or AB and B indicated that the corresponding values do
Table 5
Serum concentrations of PFCAs in Hanoi, Vietnam
Sampling Concentration (ng mL
-1
)
site Year n PFHpA PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA ΣPFCAs
Hanoi 2007- 37 GM(GSD) 0.03(1.00) 0.61(1.55) 0.89(1.47) 0.82(1.67) 1.55(1.53) 0.09(1.85) 0.36(3.38) 4.73(1.38)
2008 range <0.05 0.20-1.43 0.35-1.65 0.19-2.03 0.57-3.95 <0.10-0.26<0.10-1.99 2.58-9.43
detection% 0 100 100 100 100 51.4 86.5
GM: Geometric mean; GSD: Geometric standard deviation
Table 6
Correlation between different chain length PFCAs
Combination ρ p value
PFOA PFHpA 0.398 <0.001
PFNA PFHpA 0.223 <0.001
PFNA PFOA 0.734 <0.001
PFDA PFHpA 0.165 <0.001
PFDA PFOA 0.534 <0.001
PFDA PFNA 0.727 <0.001
PFUnDA PFHpA 0.019 0.660
PFUnDA PFOA 0.323 <0.001
PFUnDA PFNA 0.646 <0.001
PFUnDA PFDA 0.689 <0.001
PFDoDA PFHpA 0.055 0.208
PFDoDA PFOA 0.235 <0.001
PFDoDA PFNA 0.462 <0.001
PFDoDA PFDA 0.563 <0.001
PFDoDA PFUnDA 0.740 <0.001
PFTrDA PFHpA -0.117 0.008
PFTrDA PFOA 0.063 0.151
PFTrDA PFNA 0.264 <0.001
PFTrDA PFDA 0.360 <0.001
PFTrDA PFUnDA 0.552 <0.001
PFTrDA PFDoDA 0.471 <0.001
ρ: Spearman's rank correlation coefficient
Table 7
Factor analysis among PFCAs
Initial solution Varimax rotated
F1 F2 F1 F2
Eigenvalue 3.48 1.36
Contribution (%) 49.72 19.40
Eigenvector
PFHpA 0.092 0.618 -0.198 0.713
PFOA 0.365 0.480 0.327 0.819
PFNA 0.474 0.179 0.673 0.610
PFDA 0.469 0.036 0.745 0.459
PFUnDA 0.446 -0.230 0.858 0.168
PFDoDA 0.374 -0.266 0.760 0.066
PFTrDA 0.274 -0.481 0.719 -0.244
Factor score (mean±standard deviation)
Sendai 2008 0.31±0.78* -0.41±0.67*
2003 -0.84±0.90 0.17±0.92
Takayama 2008 0.50±0.67* -0.49±0.85*
2003 -0.10±0.76 0.02±0.81
Kyoto 2009 0.44±0.68* 0.68±0.52*
2002 -0.46±0.85 1.29±0.50






















Hanoi 2007- -0.27±0.74 -1.48±0.65
2008
F1: 1st factor; F2: 2nd factor
† Means among different time points are significantly different
(p<0.05 by Student's t test or Tukey's HSD test). For example,
the letters A and B indicate that the corresponding values differ
significantly at p<0.05., while A and A or B and B indicated that
the corresponding values do not differ significantly.
* Means between time points are significantly different (p<0.05
by Student's t test)
Table 8
Comparison of serum or whole blood concentrations of PFCAs with reported data
Sampling Concentration (ng mL
-1
)
site Year n Sex Sample PFHpA PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA reference
Japan
Sendai 2008 50 F median serum 0.07 2.36 1.82 0.73 2.97 0.19 0.74 This study
2003 50 F median serum 0.22 2.59 1.07 0.55 1.79 0.11 0.37 This study
Takayama 2008 50 F median serum <0.05 2.08 1.72 0.80 3.11 0.24 0.77 This study
2003 50 F median serum 0.13 3.21 1.29 0.69 2.69 0.15 0.56 This study
Kyoto 2009 15/15 M/F median serum 0.11 5.52 2.69 1.01 3.15 0.25 0.45 This study
2002 15/15 M/F median serum 0.23 7.20 2.15 0.90 1.72 0.14 0.30 This study
Osaka 2008 50 F median serum <0.05 12.80 3.32 1.10 2.98 0.19 0.72 This study
2004 10 F median serum 0.23 28.90 6.87 2.53 5.83 0.35 0.51 This study
Korea 2008 35 F median serum <0.05 4.64 1.98 0.92 3.00 0.22 0.92 This study
Busan
2000 30 F median serum <0.1 3.98 1.92 0.87 2.27 <0.2 0.76 This study
1994 39 F median serum <0.1 3.98 1.28 0.94 1.82 <0.20 0.49 This study
Seoul 2007 36 F median serum <0.05 2.21 1.11 0.57 2.37 0.14 0.74 This study
1994 24 F median serum <0.1 2.31 0.76 0.50 0.89 <0.20 <0.20 This study
Vietnam 2007- 37 F median serum <0.05 0.63 0.91 0.85 1.58 0.11 0.65 This study
Hanoi 2008
Norway 2006 >20 M median serum 0.078 2.7 0.55 0.22 0.14 <0.05 0.071 Haug et al., 2009
Sri Lanka 2003 10 M median serum 0.146 9.32 0.299 0.18 0.186 0.015 - Guruge et al., 2005
Colombo
China 2006- 8/12 M/F median pooled <0.1 3.28 0.984 0.718 0.917 <0.18 - Pan et al., 2010
Ningbo 2008 serum
Spain 2002- 24/24 M/F median whole <0.78 1.65 0.41 0.24 0.2 - - Ericson et al., 2007
Catalonia 2007 blood
Poland 2003 10/5 M/F median whole 0.086 2.8 0.49 0.17 0.078 0.012 - Falandysz et al., 2006
Gdańsk blood
Belgium 2002- 182 F pooled - 3.18 2.41 1.86 - - - Roosens et al., 2010
Antwerp 2005 serum
Australia 2006- 42/42 M/F mean pooled - 6.4 0.8 0.29 - - - Toms et al., 2009
Queensland 2007 serum
Denmark 2003 105 M median serum 0.2 4.9 0.8 0.9 0.1 0.08 <0.1 Joensen et al., 2009
Copenhagen
Sweden 1997- 40/26 M/F median whole - 2.5 0.3 0.2 0.2 - - Karrman et al., 2006
Stockholm 2000 blood
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